Testing G-CSF to Improve IVF Embryo Transfer Outcomes
The Role of Granulocyte Colony Stimulating Factor in Embryo Transfer Outcomes
This study is testing if adding a medication called G-CSF to the embryo transfer process can help improve pregnancy and live birth rates for people undergoing IVF.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 300 (estimated) |
| Ages | 18 Years to 38 Years |
| Sex | Female |
| Sponsor | Newlife Fertility Centre Industry-sponsored |
| Locations | 1 site (Mississauga, Ontario) |
| Trial ID | NCT06174298 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the impact of granulocyte colony-stimulating factor (G-CSF, also known as Filgrastim) on the outcomes of embryo transfers in patients undergoing in vitro fertilization (IVF). Participants will be randomly assigned to receive either standard embryo transfer media or G-CSF-supplemented media during their embryo transfer procedure. The study aims to determine if the addition of G-CSF can enhance clinical outcomes such as implantation rates, pregnancy rates, and live birth rates. By comparing the two groups, researchers hope to identify any significant improvements in IVF success rates.
Who should consider this trial
Good fit: Ideal candidates for this study are women undergoing fresh or frozen embryo transfer cycles as part of IVF treatment.
Not a fit: Patients with uterine factor infertility or severe male factor infertility, as well as those with previous IVF failures, may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly enhance the chances of pregnancy and live birth for patients undergoing IVF.
How similar studies have performed: While the use of G-CSF in IVF is a relatively novel approach, preliminary studies have suggested potential benefits, though further validation is needed.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Recruited subjects will either be undergoing a fresh IVF-ET cycle in which the embryo(s) generated from the initial treatment cycle are transferred during that same cycle (i.e., on day 5 or 6 post-egg retrieval) or an FET cycle in which the embryo(s) transferred were generated in a previous IVF cycle and were cryopreserved for subsequent warming and transfer. Exclusion Criteria: * Patients with uterine factor or severe male factor infertility will be excluded. * Patients who have had previous IVF failures will be excluded.
Where this trial is running
Mississauga, Ontario
- Newlife Fertility Centre — Mississauga, Ontario, Canada (Recruiting)
Study contacts
- Principal investigator: Samuel Soliman, M.D. — Newlife Fertility Centre
- Study coordinator: Samuel Soliman, M.D.
- Email: drsoliman@newlifefertility.com
- Phone: +1 905-896-7100
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.